Cancer drug bintrafusp alfa gets Long-Term safety check in small Follow-Up trial
NCT ID NCT05061823
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main goal was to track side effects, and researchers also looked at overall survival. It's a small, completed Phase 3 rollover study, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bintrafusp alfa (M7824)
What this could lead to
If successful, this study could confirm that long-term use of bintrafusp alfa is safe and helps control cancer over time.
What could go wrong
This is a small rollover study with only 22 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adana City Hospital - Parent Account
Adana, Turkey (Türkiye)
-
Asan Medical Center
Seoul, South Korea
-
BHI of Omsk region "Clinical Oncology Dispensary" - PARENT
Omsk, Russia
-
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
-
Chang Gung Memorial Hospital,Linkou
Taoyuan County, Taiwan
-
Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy
Lutsk, Ukraine
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Lazio, Italy
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
Valencia, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario Ramon y Cajal - Servicio de Oncologia
Madrid, Spain
-
NIH National Institutes of Health/GMB LTIB
Bethesda, Maryland, 20892, United States
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Japan
-
Saitama Medical University International Medical Center
Hidaka-shi, Japan
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A.
Bethesda, Maryland, 20817, United States
-
Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I
Dresden, Germany